MEDITRANS represents a multidisciplinary Integrated Project dealing with targeted nanomedicines. Platform technologies will be developed with broad applicability to disease treatment, as exemplified by the choice for chronic inflammatory disorders (rheumatoid arthritis, Crohn’s disease, multiple sclerosis), and cancer as target pathologies. Nanomedicines (based on carrier materials like polymeric and lipidic nanoparticles, nanotubes, and fullerenes) will be endowed with superior targeting and (triggerable) drug release properties. In parallel, MRI imaging probes will be designed that report on the localisation of the targeted nanomedicines, specific biomarkers, the drug release process and therapeutic outcome (imaging-guided drug delivery).
The consortium consists of 29 partners from 9 EU member states (including 1 new member state) and 3 associated states, and includes 12 industrial companies, 12 universities and 5 research institutes. The total budget is €14.8M with €10.7M as EC contribution and €4.1M as industrial support.
The MEDITRANS project has clear potential to forward targeted nanomedicines to the clinic, and will contribute to improved structural collaboration between industry and academia.
The MEDITRANS project
finished on 31.03.2011
The overall aim is to advance health care via the development of innovative targeted drug / imaging agent delivery with controlled release, and imaging guidance procedures for the detection of the underlying targeting / (triggered) drug release processes.